ChemoCentryx Inc $ 7.69 -0.23 (-2.9%)
Volume:
276,009
Avg Vol (1m):
403,760
Market Cap $:
447.95 Mil
Enterprise Value $:
269.64 Mil
P/E (TTM):
0.00
P/B:
6.25
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $7.69 | ||
Manual of Stocks™ Web
Financial Strength | 4.2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 9.47 | ||
| Equity-to-Asset | 0.31 | ||
| Debt-to-Equity | 0.3 | ||
| Debt-to-EBITDA | -0.46 | ||
| Piotroski F-Score | 1 | ||
| Altman Z-Score | -0.5 | ||
| Beneish M-Score | -3.94 | ||
| WACC vs ROIC | |||
Profitability | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -152.27 | ||
| Net Margin % | -144.27 | ||
| ROE % | -112.28 | ||
| ROA % | -23.18 | ||
| ROC (Joel Greenblatt) % | -2124.91 | ||
| 3-Year EBITDA Growth Rate | 12 | ||
| 3-Year EPS without NRI Growth Rate | 11.1 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.25 | ||
| PS Ratio | 11.87 | ||
| EV-to-EBIT | -5.77 | ||
| EV-to-EBITDA | -5.9 | ||
| EV-to-Revenue | 7.98 | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.57 | ||
| Days Sales Outstanding | 1.8 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.25 | ||
| Price-to-Median-PS-Value | 0.38 | ||
| Earnings Yield (Greenblatt) % | -17.36 |